|
| |
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
First published online September 23, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Review Article |
Prime-boost strategies for malaria vaccine development
Centre for Clinical Vaccinology and Tropical Medicine,, University of Oxford, Churchill Hospital, Old Road, Oxford OX3 7LJ, UK
* Author for correspondence (e-mail: susie.dunachie{at}ndm.ox.ac.uk)
Accepted 1 July 2003
Malaria is an intracellular pathogen, for which an effective vaccine is likely to require induction of cell-mediated immunity. Immunisation approaches that stimulate strong and persistent levels of effector T-cells are being sought by many researchers. DNA vaccines, recombinant protein and viral vectors were amongst the vaccine delivery systems that appeared promising for the generation of cellular immunity, and in some initial studies in small animals this goal was achieved. However, clinical trials of these candidate vaccines when used alone or in repeated homologous boosting regimes have been disappointing, with short-lived low levels of induced specific T-cell responses. Recent years have seen the development of immunisation strategies using a combination of different antigen delivery systems encoding the same epitopes or antigen, delivered at an interval of a few weeks apart. This sequential immunisation approach with different vectors is known as heterologous prime-boosting and is capable of inducing greatly enhanced and persistent levels of CD8+ T-cells and Th1-type CD4+ T-cells compared to homologous boosting. This review will summarise the key pre-clinical studies of prime-boost strategy and outline recent progress in clinical trials of this approach. Possible mechanisms of action and potential improvements to existing delivery systems will be discussed. The prime-boost approach represents an encouraging step towards establishing an effective preventative vaccine to one of the world's greatest killers.
Key words: vaccine, malaria, prime-boost strategy, T-cell
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
Related articles in JEB:
This article has been cited by other articles:
|
|
 |
|
  A. P. Freitas do Rosario, S. M. Muxel, S. M. Rodriguez-Malaga, L. R. Sardinha, C. A. Zago, S. I. Castillo-Mendez, J. M. Alvarez, and M. R. D'Imperio Lima Gradual Decline in Malaria-Specific Memory T Cell Responses Leads to Failure to Maintain Long-Term Protective Immunity to Plasmodium chabaudi AS Despite Persistence of B Cell Memory and Circulating Antibody J. Immunol., December 15, 2008; 181(12): 8344 - 8355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rodriguez, J. Goudsmit, A. Companjen, R. Mintardjo, G. Gillissen, D. Tax, J. Sijtsma, G. J. Weverling, L. Holterman, D. E. Lanar, et al. Impact of Recombinant Adenovirus Serotype 35 Priming versus Boosting of a Plasmodium falciparum Protein: Characterization of T- and B-Cell Responses to Liver-Stage Antigen 1 Infect. Immun., April 1, 2008; 76(4): 1709 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chinchilla, M. F. Pasetti, S. Medina-Moreno, J. Y. Wang, O. G. Gomez-Duarte, R. Stout, M. M. Levine, and J. E. Galen Enhanced Immunity to Plasmodium falciparum Circumsporozoite Protein (PfCSP) by Using Salmonella enterica Serovar Typhi Expressing PfCSP and a PfCSP-Encoding DNA Vaccine in a Heterologous Prime-Boost Strategy Infect. Immun., August 1, 2007; 75(8): 3769 - 3779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. I. Naslund, C. Uyttenhove, E. K. L. Nordstrom, D. Colau, G. Warnier, M. Jondal, B. J. Van den Eynde, and P. Liljestrom Comparative Prime-Boost Vaccinations Using Semliki Forest Virus, Adenovirus, and ALVAC Vectors Demonstrate Differences in the Generation of a Protective Central Memory CTL Response against the P815 Tumor J. Immunol., June 1, 2007; 178(11): 6761 - 6769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Castellino and R. N. Germain Chemokine-Guided CD4+ T Cell Help Enhances Generation of IL-6R{alpha}highIL-7R{alpha}high Prememory CD8+ T Cells J. Immunol., January 15, 2007; 178(2): 778 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Liang, J. V. van den Hurk, L. A. Babiuk, and S. van Drunen Littel-van den Hurk Priming with DNA encoding E2 and boosting with E2 protein formulated with CpG oligodeoxynucleotides induces strong immune responses and protection from Bovine viral diarrhea virus in cattle. J. Gen. Virol., October 1, 2006; 87(Pt 10): 2971 - 2982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Jelley-Gibbs, J. P. Dibble, S. Filipson, L. Haynes, R. A. Kemp, and S. L. Swain Repeated stimulation of CD4 effector T cells can limit their protective function J. Exp. Med., April 4, 2005; 201(7): 1101 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Korten, R. J. Anderson, C. M. Hannan, E. G. Sheu, R. Sinden, S. Gadola, M. Taniguchi, and A. V. S. Hill Invariant V{alpha}14 Chain NKT Cells Promote Plasmodium berghei Circumsporozoite Protein-Specific Gamma Interferon- and Tumor Necrosis Factor Alpha-Producing CD8+ T Cells in the Liver after Poxvirus Vaccination of Mice Infect. Immun., February 1, 2005; 73(2): 849 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Doolan, J. C. Aguiar, W. R. Weiss, A. Sette, P. L. Felgner, D. P. Regis, P. Quinones-Casas, J. R. Yates III, P. L. Blair, T. L. Richie, et al. Utilization of genomic sequence information to develop malaria vaccines J. Exp. Biol., November 1, 2003; 206(21): 3789 - 3802. [Abstract] [Full Text] [PDF]
|
|
